SciELO - Scientific Electronic Library Online

 
vol.20 issue1 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • On index processSimilars in Google

Share


Southern African Journal of HIV Medicine

On-line version ISSN 2078-6751
Print version ISSN 1608-9693

Abstract

CHIMBETETE, Cleophas; CHIRIMUTA, Linda; PASCOE, Margaret  and  KEISER, Olivia. A case report of untreatable HIV infection in Harare, Zimbabwe. South. Afr. j. HIV med. (Online) [online]. 2019, vol.20, n.1, pp.1-4. ISSN 2078-6751.  http://dx.doi.org/10.4102/sajhivmed.v20i1.885.

INTRODUCTION: Zimbabwe, like other resource limited countries, manages HIV infection using the public health approach with standard antiretroviral therapy (ART) regimens for first, second and third-line treatment. Third-line ART is the last available treatment option and is based on dolutegravir and darunavir use after HIV drug resistance testing. PATIENT PRESENTATION: We report here a 17-year-old patient on dolutegravir (DTG) and Darunavir based third-line antiretroviral therapy (ART) previously exposed to raltegravir who develops multidrug resistance HIV to the four ART classes available in Zimbabwe MANAGEMENT AND OUTCOME: A trophism assay revealed that patient has CXCR4 trophic virus and hence will not benefit from Maraviroc. Patient is currently stable and receiving a holding regimen of abacavir, lamivudine and lamivudine. CONCLUSION: This is the first documented case of multiclass resistance to the four available ART classes in Zimbabwe. The development and transmission of multiclass HIV drug resistance in resource limited settings has potential to undo the gains of national ART programs. There is need to ensure optimum adherence to ART even in the era of DTG.

Keywords : Dolutegravir; Resistance; Untreatable HIV; Zimbabwe; ART programmes.

        · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License